Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)
https://doi.org/10.14341/2072-0351-5830
Abstract
Individualization of treatment goals is a modern trend in diabetology. During 47th Annual Meeting of European Association for the Study of Diabetesthis very problem was addressed repeatedly. The Sanofi Satellite Symposium under the name A step towards individualizing care to achieve earlyand sustained glycemic control presented lectures of worlds leading experts, giving priority to the problem of early diagnosis and early interventionfor individuals with T2DM, as well as potential benefits of early insulinisation, significance of adequate self-monitoring and pharmacoeconomicaspects of diabetes care.
Keywords
EASD,
diabetes mellitus,
EASD,
insulin glargin,
insulin glulisin,
insulin therapy,
exenatide,
lixisenatide
About the Authors
Ivona Renata Yarek-Martynova
Endocrinology Research Centre, Moscow
Lyubov' Leonidovna Bolotskaya
Endocrinology Research Centre, Moscow
References
1. Skyles J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A., Howard B.V., Kirkman M.S., Kosiborod M., Reaven P., Sherwin R.S. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association // Circulation. - 2009. - № 119 (2). - Р. 351-357.
2. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // New. Engl. J. Med. - 2008. - № 358(24). - Р. 2560-2560.
3. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes // New. Engl. J. Med. - 2008. - № 358 (24). - Р. 2545-2559.
4. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vitek M.E., Henderson W.G., Huang G.D. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes // New. Engl. J. Med. - 2009. - № 360 (2). - Р. 129-139.
5. Prato S.D., LaSalle J., Matthaei S., Bailey С.J. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management // Int. J. Clin.Prac. - 2010. - № 64(3). - Р. 295-304.
6. Tumbull F.M. Intensive glucose control and macrovascular outcomes in type 2 diabetes // Diabetologia. - 2009. - № 52(11). - Р. 2288-98.
7. Gerstein H.C., Yusuf S., Riddle M.C., Ryden L., Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) // Am. Heart. J. - 2008. - № 155(1). - Р. 26-32.
8. Yki-Jarvinen H. Nonglycemic effects of insulin // Clin. Cornerstone. - 2003. - Suppl. 4. - S6-12.
9. Weng J., Li Y., Xu W., Shi L., Zhang Q., Zhu D., Hu Y., Zhou Z., Yan X., Tian H., Ran X., Luo Z., Xian J., Yan L., Li F., Zeng L., Chen Y., Yang L., Yan S., Liu J., Li M., Fu Z., Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial // Lancet. - 2008. - № 371. - Р. 1753-1760.
10. Makimattila S., Nikkilä K., Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus // Diabetologia. - 1999. - № 42(4). - Р. 406-412.
11. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes // New. Engl. J. Med. - 2008. - № 359(15). - Р. 1577-1589.
12. Yki-Jarvien H., Kauppinen-Mäkelin R., Tiikkainen M., Vähätalo M., Virtamo H., Nikkilä K., Tulokas T., Hulme S., Hardy K., McNulty S., Hänninen J., Levänen H., Lahdenperä S., Lehtonen R., Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study // Diabetologia. - 2006. - № 49 (3). - Р. 442-451.
13. Garg S.K., Moser E., Dain M.P., Rodionova A. Clinical experience with insulin glargine in type 1 diabetes // Diabetes Care. - 2010. - № 12(11). - Р. 835-846.
14. Garg S.K., Ampudia-Blasco F.J., Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus // Endocr. Pract. - 2010. - № 16(3). - Р. 486-505.
15. Garg S.K., Rosenstock J., Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine // Endocr. Pract. - 2005. - № 11(1). - Р. 11-17.
16. Riddle M.C., Rosenstock J., Gerich J. Insulin Glargine 4002 Study Investigators The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients // Diabetes Care. - 2003. - № 26(1). - Р. 3080-3086.
17. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P. Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucoselowering drugs in insulin-naive people with type 2 diabetes // Diabetes Care. - 2006. - № 29(6). - Р. 1269-1274.
18. Fritsche A., Larbig M., Owens D., Häring H.U. GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study // Diabetes Obes Metab. - 2010. - № 12(2). - Р. 115-123.
19. Bergenstal R.M., Johnson M., Powers M.A., Wynne A., Vlajnic A., Hollander P., Rendell M. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine // Diabetes Care. - 2008. - № 31(17). - Р. 1305-1310.
20. Borchers A.T. The geoepidemiology of type 1 diabetes // Autoimmun Rev. - 2010. - № 9(5). - Р. A355-365.
21. Eisenbarth G.S. Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes // Diabetes. - 2010. - № 59(4). - Р. 759-774.
22. Skyler J.S., Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man // Diabetes. - 2011. - № 60(1). - Р. 1-8.
23. Cernea S. Prevention of type 1 diabetes: today and tomorrow // Diabetes Metab Res Rev. - 2010. - № 26(8). - Р. 602-605.
24. Alehandro R. Update from the Collaborative Islet Transplant Registry // Transplantation. - 2008. - № 86(12). - Р. 1783-1788.
25. Halban P.A., et al. Current status of islet cell replacement and regeneration therapy // J. Clin. Endocrinol. Metab. - 2010. - № 95(3). - Р. 1034-43.
26. Juhl K., et al. Regenerating pancreatic beta-cells: plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis // Curr. Opin. Organ. Transplant. - 2010. - № 15(1). - Р. 79-85.
27. Reutens A.T. Diabetes: individualized therapy for diabetes mellitus - just a promise? // Nat Rev Endocrinol. - 2010. - № 6. - Р. 426-427.
28. Smith R.J., Nathan D.M., Arslanian S.A., Groop L., Rizza R.A., Rotter J.I. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know // J. Clin. Endocrinol. Metab. - 2010. - № 95. - Р. 1566-1574.
29. Pozzilli P., Leslie R.D., Chan J. etal.TheAICand ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach // Diabetes Metab Res Rev. - 2010. - №. 26. - Р. 239-244.
30. Tsapas A., Matthews D.R. N of 1 trials in diabetes: making individual therapeutic decisions // Diabetologia. - 2008. - № 51. - Р. 921-925.
31. Davis S.N., Johns D., Maggs D., Xu H., Northrup J.H., Brodows R.G. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents // Diabetes Care. - 2007. - № 30. - Р. 2767-2772.
32. Gerich J., Fonseca V., Alvrdo-Ruiz R. et al. Monotherapy with GLP-1 receptor agonist, Lixisenatide, significantly improves glycaemic control in type 2 diabetic patients // Diabetologia. - 2010. - № 53. - Р. A830.
33. Kendall D.M., Riddle M.C., Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea // Diabetes Care. - 2005. - № 28. - Р. 1083-1091.
34. Nauck M.A., Duran S., Kim D. et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study // Diabetologia. - 2007. - № 50. - Р. 259-267.
35. Zinman В., Gerich J., Buse J.B. et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) // Diabetes Care. - 2009. - № 32. - Р. 1224-1230.
36. Buse J.В., Bergenstal R.M., Glass L.C. et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial // Ann Intern Med. - 2011. - № 154. - Р. 103-112.
37. John L.A., Kane M.R., Busch R.S., Hamilton R.A. Expanded use of exenatide in the mangement of type 2 diabetes // Diabetes Spectrum. - 2007. - № 20. - Р. 59-63.
38. Levin P.A., Mersey J.H., Zhou S., Bromberger L.A. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes // Endocr. Pract. 2011 :(online publication), http://aace.metapress.com/ content/x7j3534018867177/ fulltext.pdf (last accessed 5/09/2011).
39. Sheffield C.A., Kane M.R., Busch R.S., Bakst G., Abelseth J.M., Hamilton R.A. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus // Endocr. Pract. - 2008. - № 14. - Р. 285-292.
40. Viswanathan P., Chaudhuri A., Bhatia R., Al-Atrash R., Mohanty P., Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin // Endocr. Pract. - 2007. - № 13. - Р. 444-450.
41. Yoon N.M., Cavaghan M.K., Brunelle R.L., Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting // Clin. Ther. - 2009. - № 31. - Р. 1511-1523.
42. Seino Y., Min K., Niemoller E., Takami A. Lixisenatide significantly improves glycemic control in Asian patients with T2DM insufficiently controlled on basal insulin ± SU // Diabetes. - 2011. - № 60(Suppl.1):A278.
43. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP // Gastroenterology. - 2007. - № 132(6). - Р. 2131-2157.
44. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.M., Zhou Y.Q., Riazi A.M., Baggio L.L., Henkelman R.M., Husain M., Drucker D.J. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice // Diabetes. - 2009. - № 58(4). - Р. 975-983.
45. Okerson T., Chilton R.J. The Cardiovascular Effects of GLP-1 Receptor Agonists // Cardiovasc Ther. - 2010. - № 1-10.
46. Arakawa M., Mita T., Azuma K., Ebato C., Goto H., Nomiyama T., Fujitani Y., Hirose T., Kawamori R., Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4 // Diabetes. - 2010. - № 59(4). - Р. 1030-1037.
47. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., Parker T.G., Huang Q., Drucker DJ., Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor // Endocrinology. - 2003. - № 144(6). - Р. 2242-2252.
Review
For citations:
Yarek-Martynova I.R., Bolotskaya L.L. Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting). Diabetes mellitus. 2011;14(4):115-119. (In Russ.) https://doi.org/10.14341/2072-0351-5830
Views:
979
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
